Two new studies suggest older men and women taking selective serotonin reuptake inhibitors, a class of antidepressants that includes Prozac, Paxil and Zoloft, are prone to increased bone loss.
The jointly released studies by scientists at Oregon Health & Science University, and in San Francisco, Minneapolis, San Diego and Pittsburgh, found that elderly men taking the so-called SSRIs had lower bone mineral density, and that elderly women taking the antidepressants had a higher rate of yearly bone loss.
The studies appear in today's issue of Archives of Internal Medicine, a publication of the Journal of the American Medical Association.
The studies "raise some concern about people taking SSRIs and whether they may need additional screening or extra protection for their bones," said Elizabeth Haney, M.D., assistant professor of medicine (general internal medicine and geriatrics) in the OHSU School of Medicine who led the men's study and co-authored the women's study.
But Haney cautioned the studies' results don't confirm a "cause-and-effect relationship" between SSRIs and bone loss. "Both are observational studies, so without a prospective study of this issue, we're unable to make a determination of direct causality," she said.
The studies also found that use of another popular class of antidepressant medications, known as tricyclic antidepressants or TCAs, were not associated with increased bone loss in men and women. TCAs include such drugs as amitriptyline (Elavil), desipramine (Norpramin), doxepin (Sinequan), imipramine (Tofranil) and nortriptyline (Pamelor).
For the men's study, which measured total bone loss, researchers analyzed health data for 5,995 men ages 65 and older who were recruited from six regions of the United States between March 2000 and April 2002. They found that bone mineral density among SSRI users was 3.9 percent lower at the total hip and 5.9 percent lower at the lumbar spine compared with men not taking the antidepressants.
For the women's study, a longitudinal study measuring bone loss rate, researchers first examined 2,722 women ages 65 and older from four regions between 1986 and 1988, and again between 1997 and 1998. Bone mineral density in the total hip decreased .47 percent among participants who didn't use SSRIs, but .82 percent among people who did take the drugs.
Michael Bliziotes, M.D., OHSU associate professor of medicine (endocrinology, diabetes and clinical nutrition) who was senior author on the men's study and co-author on the women's study, said the research team was "surprised at the degree of difference we saw. I wasn't anticipating it would be that much."
That's because there are so many other factors that could affect bone density, the researchers said. For example, older men taking SSRIs have lower physical activity or greater intake of alcohol. And older women tend to be more depressed than men, and they lose bone density at a greater rate earlier in life due to menopause.
"One of the concerns we had was depression has its own effects on bones, so depressed people probably have lower bone density independent of their SSRI use," Bliziotes said. "Still we found that the bone density was lower in SSRI users even after controlling for as many confounding variables as we could."
Haney and Bliziotes both agree the results don't mean people taking antidepressants, even SSRIs, should stop.
"Depression is a serious condition and it's important not to stop antidepressants abruptly or without talking to your physician," Haney said. "However, it may be worth paying special attention to the things we know can prevent osteoporosis, such as exercise, taking adequate calcium and vitamin D, and it might be worth consideration of screening for low bone density."
Bliziotes added, "We don't want to leave anyone with the impression that if they're on an SSRI for a valid reason, they should go off it. They have benefits, they've been demonstrated, and people have been put on them for valid reasons, so we don't want to do anything that would jeopardize that."
Haney said future studies will continue to track bone density changes over time to help researchers determine the effects of SSRI use on markers of bone cell turnover.
Jonathan Modie | EurekAlert!
Diagnoses: When Are Several Opinions Better Than One?
19.07.2016 | Max-Planck-Institut für Bildungsforschung
High in calories and low in nutrients when adolescents share pictures of food online
07.04.2016 | University of Gothenburg
Researchers from the Institute for Quantum Computing (IQC) at the University of Waterloo led the development of a new extensible wiring technique capable of controlling superconducting quantum bits, representing a significant step towards to the realization of a scalable quantum computer.
"The quantum socket is a wiring method that uses three-dimensional wires based on spring-loaded pins to address individual qubits," said Jeremy Béjanin, a PhD...
In a paper in Scientific Reports, a research team at Worcester Polytechnic Institute describes a novel light-activated phenomenon that could become the basis for applications as diverse as microscopic robotic grippers and more efficient solar cells.
A research team at Worcester Polytechnic Institute (WPI) has developed a revolutionary, light-activated semiconductor nanocomposite material that can be used...
By forcefully embedding two silicon atoms in a diamond matrix, Sandia researchers have demonstrated for the first time on a single chip all the components needed to create a quantum bridge to link quantum computers together.
"People have already built small quantum computers," says Sandia researcher Ryan Camacho. "Maybe the first useful one won't be a single giant quantum computer...
COMPAMED has become the leading international marketplace for suppliers of medical manufacturing. The trade fair, which takes place every November and is co-located to MEDICA in Dusseldorf, has been steadily growing over the past years and shows that medical technology remains a rapidly growing market.
In 2016, the joint pavilion by the IVAM Microtechnology Network, the Product Market “High-tech for Medical Devices”, will be located in Hall 8a again and will...
'Ferroelectric' materials can switch between different states of electrical polarization in response to an external electric field. This flexibility means they show promise for many applications, for example in electronic devices and computer memory. Current ferroelectric materials are highly valued for their thermal and chemical stability and rapid electro-mechanical responses, but creating a material that is scalable down to the tiny sizes needed for technologies like silicon-based semiconductors (Si-based CMOS) has proven challenging.
Now, Hiroshi Funakubo and co-workers at the Tokyo Institute of Technology, in collaboration with researchers across Japan, have conducted experiments to...
14.10.2016 | Event News
14.10.2016 | Event News
12.10.2016 | Event News
21.10.2016 | Health and Medicine
21.10.2016 | Information Technology
21.10.2016 | Materials Sciences